PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV

Foundayo (orforglipron) vs Wegovy (semaglutide) - Which oral tablet is better?

18:08Apr 2026

Today’s cheapest Wegovy$208/mo at Sesame Care, an average: a $59/mo subscription billed $708 once a year, with medication billed monthly.Compare all Wegovy prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. Not from the video’s creator.

Our summary

The channel compares two oral weight loss tablets: Foundayo (orforglipron) from Lilly and Wegovy (semaglutide) from Novo Nordisk. The host says the FDA approved Foundayo on April 1st, 2026, and that Lilly stresses it can be taken any time of day without food or water restrictions. By contrast, the host reads out the Wegovy label, which says to take the tablet on an empty stomach in the morning with no more than 4 ounces of water, then wait 30 minutes before eating, drinking or taking other oral medications. The host does not think this is very limiting for most people.

Published by PharmaTalks on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

The host then reviews published trials in adults without type 2 diabetes: ATTAIN 1 for orforglipron and OASIS 1 and OASIS 4 for oral semaglutide. He says OASIS 4 showed 13.6 percent weight loss with semaglutide 25 mg in the real-world style analysis. In the hypothetical analysis assuming full adherence, he cites 17.4 percent in OASIS 1, 16.6 percent in OASIS 4 and about 12.4 percent in ATTAIN 1. He calls the orforglipron result substantial but lower. He also describes Novo Nordisk's indirect comparison press release, which he says he treats with caution, and notes that none of this comes from head to head trials.

For people with type 2 diabetes, he compares ATTAIN 2 and PIONEER PLUS, and stresses that the patients did not start at the same BMI. He says side effects, including nausea, vomiting and diarrhea, look broadly similar across the trials. His personal conclusion is that he would choose oral semaglutide and expects it to take most of the oral market. He adds that he is not a doctor and that viewers should speak with a medical professional.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 1:12 The host says the FDA approved Foundayo (orforglipron) on April 1st, 2026, and that Lilly highlights the lack of food and water restrictions.
  2. 2:14 He reads the Wegovy tablet label: take it on an empty stomach with no more than 4 ounces of water, then wait 30 minutes before eating or drinking.
  3. 4:49 He describes Novo Nordisk's indirect comparison of semaglutide 25 mg and orforglipron 36 mg, and says he is hesitant to rely on such comparisons.
  4. 10:31 In the full adherence analysis without type 2 diabetes, he cites 17.4 percent weight loss in OASIS 1, 16.6 percent in OASIS 4 and about 12.4 percent in ATTAIN 1.
  5. 13:09 In people with type 2 diabetes, he cites 9.6 percent weight loss on orforglipron in ATTAIN 2 and about 8.5 percent on semaglutide in PIONEER PLUS, and cautions that baseline weights differed.
  6. 16:46 He concludes he would choose oral semaglutide and expects it to take most of the oral tablet market, while saying this is only his opinion.

Key moments

Tap one to play from there.

  1. 0:11 Introduction
  2. 5:17 The trials
  3. 9:10 Dose change
  4. 12:29 Side effects
  5. 13:37 The trials
  6. 16:30 Side effects

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Wegovy, Foundayo and semaglutide
Side effects mentioned
nausea, vomiting and diarrhea

Questions this video answers

What is the difference between how Foundayo and Wegovy tablets are taken?

According to the video, Lilly says Foundayo (orforglipron) can be taken any time of day without food or water restrictions. The Wegovy tablet label, as read by the host, says to take it on an empty stomach in the morning with no more than 4 ounces of water, then wait 30 minutes before eating, drinking or taking other oral medications.

Does Wegovy pill or Foundayo cause more weight loss?

The host says semaglutide appears more effective, citing 16.6 to 17.4 percent weight loss in OASIS trials versus about 12.4 percent in ATTAIN 1 under full adherence. He cautions these are not head to head trials and that orforglipron's weight loss is still substantial.

Are the side effects of Foundayo and Wegovy tablets different?

The host says adverse event rates were broadly similar across the trials, with roughly 80 to 90 percent of patients reporting any adverse event. He notes maybe slightly more nausea and vomiting with semaglutide in people without diabetes, and slightly higher diarrhea with orforglipron in people with type 2 diabetes.

Which oral weight loss pill does the host prefer?

He says that if he were the person he would probably choose oral semaglutide because it seems the most efficacious with no major safety differences. He stresses this is his opinion and not medical advice.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • The best GLP-1 for weight loss, ranked by the evidence and then by the bill

    By weight lost, the order is settled: tirzepatide (Zepbound) first at 20.2% in the only head-to-head, then semaglutide 7.2 mg (Wegovy HD) at 18.7%, then semaglutide 2.4 mg (Wegovy) at 13.7% to 15.6%, then the pills. By what you pay, the order nearly inverts: compounded semaglutide from $39 a month, the Wegovy tablet from $149, Wegovy pen $349, Zepbound $299 to $699 by dose. The best one is where those two lists meet for your budget and your plan.

  • Foundayo vs Wegovy pill: two weight-loss tablets, two molecules, the same $149 start

    Foundayo is orforglipron, the Wegovy pill is semaglutide. Both start at $149 a month self-pay. Foundayo has no food or water rules; that is Lilly's main claim.

  • Mounjaro vs Ozempic, and the trial everyone quotes about it

    Mounjaro is tirzepatide and Ozempic is semaglutide: different molecules, not two brands of the same drug. Both are approved for type 2 diabetes, and the weight-loss versions are Zepbound and Wegovy. In the one head-to-head trial, SURMOUNT-5, tirzepatide produced 20.2% mean body-weight loss at 72 weeks against semaglutide's 13.7%. The detail almost every page omits: that trial dosed semaglutide to 2.4 mg in people without diabetes, which is the Wegovy range. Ozempic tops out at 2 mg. The famous result did not test Ozempic's dose range.

Next steps

Wegovy prices

Insurance

Find more like it

Side effectsDose changeStopping and maintenanceThe trialsNauseaVomitingDiarrhea

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV